Panitumumab 6mg/kg and FOLFIRI Therapy-14 day. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Panitumumab 6mg/kg and FOLFIRI Therapy-14 day, 2023, version number 4a, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/448%20panitumumab-6mg-kg-and-folfiri-therapy-14-day.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
First line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC).	1
Second line treatment of adult patients with wild-type RAS mCRC who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Irinotecan, Panitumumab
Sensitivity (+)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Irinotecan, Panitumumab